Full video transcriptClick to expand
Auto-generated transcript of @bossfidence's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Hey everybody, so I'm so sorry I forgot to do my week 4 update last week
- 0:05So I'm gonna kind of do a mixture of my week 4 and week 5 so I was actually supposed to dose up
- 0:11Week 4 however, my provider didn't have that increased dose for me
- 0:16And then she went on vacation so I haven't been able to get my increased dose
- 0:19From everything that I've read on like reddit and things like that is that when you plateau you need to increase dose
- 0:24And I have plateaued I haven't been able to lose anything more than those 8.2 pounds that I've lost
- 0:29So instead of focusing on like the fact that I'm not losing
- 0:33I'm mostly focusing on like non scale things that I can do to improve my life
- 0:38So that's going to be increasing my protein increasing my cardio
- 0:43Increasing my fiber really being mindful about you know, what I'm eating how I'm eating very intentional
- 0:51Really just creating more lifestyle habits from how I'm eating
- 0:55I do want to talk to you guys about some side effects that I've had
- 0:58I should I'm gonna do a completely different video for that because I do think it's important to talk about the different side effects that different people have
- 1:05Just so that way you can expect
- 1:07Know what to expect if you decide to get on the semagluetide shots
- 1:11So in the last two weeks like I said I haven't been able to I haven't lost any additional weight
- 1:16However, I am noticing a huge difference in my muscle tone over my all around my body because I am going to the gym
- 1:244 to 5 days a week doing lots of heavy lifting cardio
- 1:30High intensity interval style workouts
- 1:33I do group personal training with my mom at our local anytime business and I absolutely love it
- 1:38It has been such a game changer. I've been going for a little over two months really consistently at least three to five days a week
- 1:44And I've noticed like a huge difference and today for example
- 1:48Right before I did my injection
- 1:49I was looking at myself in the mirror and I was like oh my gosh like my legs are looking super toned and like my cellulite
- 1:55It's kind of reduced a little bit
- 1:57So those are the kind of things that I'm mostly working on I think that it's really important for me as someone with PCOS who hasn't been able to really
- 2:04lose weight in a
- 2:07Sustainable fashion over the last seven years
- 2:10To really focus on the slow and steady wins the race when it comes to my weight loss and the semagluetide journey
- 2:17So like I said, I'm gonna do another video about the side effects that I've been having
- 2:21But that was my week four and five update no weight loss. However, noticing a huge difference in my muscle tone
Semaglutide for PCOS weight loss: what weeks 4-5 actually mean
Quick answer
The creator is a woman with PCOS and documented insulin resistance using semaglutide for weight management. She has been at a starting dose for approximately five weeks without escalation due to a provider availability issue, and reports an 8.2-pound loss followed by a two-week plateau. She is actively supplementing with resistance training and HIIT, which complicates scale-based progress tracking due to likely concurrent muscle accrual.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Semaglutide for PCOS weight loss: what weeks 4-5 actually mean, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Compounded Semaglutide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Semaglutide for PCOS weight loss: what weeks 4-5 actually mean" from Ashley | Bossfidence. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator is a woman with PCOS and documented insulin resistance using semaglutide for weight management.
The reason this review is not generic is the source wording and the canonical claim label "glp1 semaglutide week 4 5 update doing a separate video right aft." In this clip, the useful excerpt is: "Hey everybody, so I'm so sorry I forgot to do my week 4 update last week So I'm gonna kind of do a mixture of my week 4 and week 5 so I was actually supposed to dose up Week 4 however, my provider didn't have that increased dose for me And..." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The creator is a woman with PCOS and documented insulin resistance using semaglutide for weight management.
FormBlends verdict
Compounded Semaglutide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator is a woman with PCOS and documented insulin resistance using semaglutide for weight management. She has been at a starting dose for approximately five weeks without escalation due to a provider availability issue, and reports an 8.2-pound loss followed by a two-week plateau. She is actively supplementing with resistance training and HIIT, which complicates scale-based progress tracking due to likely concurrent muscle accrual.
- The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide's weight loss effect builds over 68 weeks, so a two-week plateau at starting dose is not a clinical emergency requiring immediate escalation.
- Reddit is not a substitute for provider guidance on dose titration. Faster escalation than the standard four-week schedule increases GI side effect risk and is a leading cause of early discontinuation.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide's weight loss effect builds over 68 weeks, so a two-week plateau at starting dose is not a clinical emergency requiring immediate escalation.
- Reddit is not a substitute for provider guidance on dose titration. Faster escalation than the standard four-week schedule increases GI side effect risk and is a leading cause of early discontinuation.
- Standard semaglutide titration starts at 0.25mg weekly and increases every four weeks, a schedule set for tolerability, not just efficacy.
- Women with PCOS may have altered weight loss patterns due to insulin resistance. GLP-1 agents appear to help with this mechanism, but metabolic monitoring by a provider is warranted (Cena et al., 2020, Nutrients).
- Body recomposition during heavy resistance training can produce visible changes in muscle tone and fat distribution without scale movement, making weight alone a poor progress metric.
- A plateau explanation does not require a drug explanation. Adaptive metabolic responses to caloric restriction can stall weight loss independently, as documented by Hall and Guo (2017, Cell Metabolism).
- The creator's decision to wait for her provider rather than self-escalate is the correct call, and worth naming explicitly given how common unsupervised dose increases are in online GLP-1 communities.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @bossfidence actually say?
In her combined week 4 and 5 update, the creator reported no additional weight loss beyond her initial 8.2 pounds, attributing the plateau to being stuck at her starting dose because her provider went on vacation. She cited Reddit as her source for the idea that "when you plateau you need to increase dose." She also credited visible muscle tone changes and cellulite reduction to consistent gym training, four to five days a week, despite the scale not moving. Her overall framing was measured: slow progress is still progress, especially with PCOS in the picture.
To her credit, she did not self-dose, did not order a higher dose on her own, and explicitly said she was waiting on her provider. That matters. A lot of people in her position do not wait.
Does the science back this up?
On the dose-plateau connection, she is mostly right, but the nuance matters. The clinical trial data does support that higher semaglutide doses produce greater weight loss, but a plateau at week 4 or 5 on a starting dose is not necessarily a problem that requires escalation right now. Early plateaus are common.
The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed that the bulk of semaglutide's weight loss effect accumulates over 68 weeks, with dose escalation happening gradually over 16 to 20 weeks. A two-week stall at the lowest dose is not a clinical red flag. Reddit, predictably, skips this context entirely. What the data actually says is that dose titration schedules exist for tolerability reasons as much as efficacy ones, and pushing faster carries a higher side effect burden, including nausea and GI distress.
On the muscle tone and cellulite front, the changes she describes are real and plausible. Resistance training combined with even modest caloric adjustment can meaningfully shift body composition without scale movement. This is well-documented, and she deserves credit for focusing on it.
What did they get wrong (or right)?
The Reddit-as-medical-advice problem is real here. Saying "from everything I've read on Reddit" when discussing dose escalation is the kind of thing that should come with a warning label. Online communities for GLP-1 users frequently promote faster titration than clinical protocols support, and that advice has contributed to unnecessary side effects and medication discontinuation.
She did not get the mechanism wrong, exactly. Higher doses do correlate with greater appetite suppression. But the framing that a plateau means you need more drug ignores other explanations: water retention, muscle gain offsetting fat loss, or simply the body adjusting. A study by Hall and Guo (2017, Cell Metabolism) showed that the body has significant adaptive responses to caloric restriction that can stall weight loss independently of any drug effect.
What she got right is her pivot. Increasing protein, fiber, and resistance training while waiting for provider guidance is genuinely sound practice. The STEP 1 data showed that lifestyle intervention alongside semaglutide produced better outcomes than the drug alone. Her instinct to focus on those variables is clinically reasonable, even if she found it through trial and error rather than a care team conversation.
What should you actually know?
If you are on semaglutide and you hit a plateau, the first call should be to your provider, not Reddit. Dose escalation decisions should account for your current side effect profile, how long you have been at the current dose, and your overall metabolic picture. The standard titration schedule for semaglutide starts at 0.25mg weekly and moves up every four weeks, and that pace exists for real reasons.
For people with PCOS specifically, weight loss patterns can be genuinely different. Insulin resistance, which she tags in her post, affects how the body responds to caloric deficits, and GLP-1 receptor agonists do appear to help with this mechanism. A small but notable trial by Cena et al. (2020, Nutrients) found improved metabolic markers in women with PCOS using GLP-1 agents, though the sample sizes were limited. The creator is not wrong to think semaglutide may be particularly relevant to her condition, but that is a conversation for her endocrinologist, not a TikTok comment section.
Finally, the muscle tone observation is worth taking seriously. Body recomposition, gaining muscle while losing or maintaining fat, can make the scale a genuinely misleading metric. Progress photos and measurements often tell a more accurate story during active resistance training programs.
Is there anything missing from her update?
Yes. She mentions side effects will be covered in a separate video, which is fine, but side effects at week 4 to 5 are often the most clinically relevant piece of information for someone considering this medication. GI symptoms, fatigue, and injection site reactions peak in the early titration phase for many users. Anyone using this video to calibrate expectations should look for that follow-up before drawing conclusions about tolerability.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Ashley | Bossfidence · TikTok creator
25.1K views on this video
#semaglutide week 4 & 5 update! Doing a separate video right after this to talk about my side effects I’ve experienced over the last month. #weightlosscheck #mounjaro #ozempic #wegovy #pcos #pcosweightloss #insulinresistance
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about the step 1 trial (wilding et al., 2021, nejm) showed?
The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide's weight loss effect builds over 68 weeks, so a two-week plateau at starting dose is not a clinical emergency requiring immediate escalation.
What does the video say about reddit?
Reddit is not a substitute for provider guidance on dose titration. Faster escalation than the standard four-week schedule increases GI side effect risk and is a leading cause of early discontinuation.
What does the video say about standard semaglutide titration starts at 0.25mg weekly?
Standard semaglutide titration starts at 0.25mg weekly and increases every four weeks, a schedule set for tolerability, not just efficacy.
What does the video say about women with pcos may have altered weight loss patterns due?
Women with PCOS may have altered weight loss patterns due to insulin resistance. GLP-1 agents appear to help with this mechanism, but metabolic monitoring by a provider is warranted (Cena et al., 2020, Nutrients).
What does the video say about body recomposition during heavy resistance training can produce visible changes?
Body recomposition during heavy resistance training can produce visible changes in muscle tone and fat distribution without scale movement, making weight alone a poor progress metric.
What does the video say about a plateau explanation does not require a drug explanation. adaptive?
A plateau explanation does not require a drug explanation. Adaptive metabolic responses to caloric restriction can stall weight loss independently, as documented by Hall and Guo (2017, Cell Metabolism).
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Ashley | Bossfidence, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.